Krystal Biotech 3Q 2026 Conference Call - KRYSTAL BIOTECH INC

Financial Performance:

• Reported Q3 2026 net revenue of $127.3 million for Vizivac (Vizivic/Vijuvec/Vigevec), a 30% year-over-year increase; Q3 2025 revenue was $97.8 million.
• U.S. net revenue reached $95.3 million, driven by over 760 reimbursement approvals and the addition of 80+ new prescribers.
• International revenue was $32 million, with pricing negotiations concluded in Germany, Japan, and Italy, and Spain expected to finalize before year-end.
• Diluted earnings per share (EPS) were $2.05, with net income of $63.1 million; prior year Q3 net income was $79.4 million (influenced by non-recurring tax reversals).
• Gross margin was 94%, down 200 basis points from 96% in Q3 2025 due to higher sales volume in Europe/Japan with non-optimized manufacturing and lower-cost R&D batches sold in the prior year.
• Total cash and investments exceeded $1.2 billion as of September.
• Operating expenses included $14.9 million in R&D (down from $146 million, likely a typo in transcript for $14.6M or similar; context suggests lower spend) and $33.7 million in G&A, offset by $13.9 million in non-cash stock-based compensation.
• Revised full-year non-GAAP R&D and SG&A guidance to $155–$165 million from a previous range of $175–$195 million.

Guidance and Future Outlook:

• Authorized a new share repurchase program of up to $400 million to be deployed over the next two years, reflecting confidence in long-term prospects and capital flexibility.
• Expect to launch Vizivac in Italy in early 2027 and potentially in Spain next year following pricing decisions.
• Clinical readouts: KB803 (ocular DEB) top-line results expected shortly after the last patient visit in February 2027; KB801 (Netherton syndrome) enrollment and top-line results expected in 2027.
• KB407 (Cystic Fibrosis) interim results anticipated in the first half of 2027, with a potential registrational study starting in 2027.
• KB707 (Haley-Haley) data update expected before year-end; KB113 (Gorlin Syndrome) engaging with FDA regarding development pathways.
• International growth drivers include pricing stability in key markets and the shift to monthly dosing in Japan to improve patient access.

Business Segments and Product Lines:

• Vizivac (DEB Treatment): Strong global commercial performance; U.S. adoption is high with 80% of patients self-administering; international expansion accelerating with new centers in Germany and France enabling home administration.
• KB113 (Gorlin Syndrome): Pilot study in 3 patients showed >80% lesion regression and histological confirmation of complete clearance in injected tumors; evidence of abscopal (systemic) effect observed.
• KB801 (Netherton Syndrome): Enrollment progressing slower than expected due to stringent inclusion/exclusion criteria and competition from commercial Oxervate; expanding to European sites to accelerate recruitment.
• KB803 (Ocular DEB): Registrational study active; enrolled 3 additional patients including a 1-year-old to support pediatric labeling; last patient visit expected Feb 2027.
• KB407/KB408 (CF/AATD): Dosing ongoing; confirming successful gene delivery via biopsies; engaging with FDA under the Complex Innovative Design Meeting program.
• KB707 (Oncology): Dose optimization completed for the KINITE-1 expansion cohort; targeting 70 patients by mid-2027.

Market and Competitive Landscape:

• U.S. market sees growing prescriber base and significant opportunity among undiagnosed or misdiagnosed DEB patients.
• In France, pricing negotiations are ongoing with a typical 13-month timeline; currently six months into the process.
• In Spain, exceptional regional funding provides early patient access while national pricing is finalized.
• Netherton syndrome program faces competition from Oxervate in the U.S., necessitating rigorous enrollment criteria and European expansion where Oxervate is unavailable.
• Healthcare systems are increasingly recognizing the value of genetic medicines like Vizivac, leading to broader reimbursement and treatment networks.

Risks and Challenges:

• Clinical Delays: Slower-than-anticipated enrollment in Netherton syndrome (KB801) and Ocular DEB (KB803) due to small patient populations, stringent criteria, and patient availability (e.g., travel, competing trials).
• Manufacturing Margins: Gross margin pressure from non-optimized manufacturing processes in international markets compared to the U.S.
• Regulatory Timelines: Dependent on FDA alignment for pipeline programs (Gorlin, Haley-Haley, CF) and national pricing negotiations in Europe (France, Spain) to unlock full market potential.
• Patient Adherence: Challenges in ensuring patient compliance in clinical trials for difficult-to-treat rare diseases.

Management Commentary and Tone:

• Tone was confident and forward-looking, emphasizing the transition to profitability, global commercial scale, and a robust pipeline.
• Management expressed pride in the $1.1 billion cumulative Vizivac revenue and the ability to return capital to shareholders via buybacks.
• Acknowledged delays in clinical data releases but maintained that programs are progressing well and will deliver results in the "upcoming months."
• Emphasized the strategic value of building a global platform for genetic medicines beyond the initial DEB indication.

Analyst Questions and Answers:

• KB407 Enrollment: Additional 3 patients enrolled in CF study not due to dose changes but to maintain momentum; data expected mid-2027. Japan adoption expected to accelerate post-year mark as dosing frequency decreases (twice to once monthly).
• Netherton (KB801) Enrollment: Expansion into 10-15 new U.S. sites and aggressive site activation in EU to overcome screen failures caused by spontaneous lesion healing; inclusion criteria strictly exclude patients with lesion reduction between screenings.
• Capital Allocation: CFO and CEO confirmed $1.2B cash position allows for buybacks while funding pipeline; management open to increasing R&D spend if it directly accelerates enrollment or study conduct.
• France Pricing: Confirmed standard 13-month negotiation timeline; currently six months in, proceeding normally.
• Gorlin (KB113) Study Design: Expect pivotal trial to be small (<100 patients) given high response rates and lack of spontaneous healing; FDA engagement ongoing.
• Ocular DEB Analysis: Withdrawing patients will be included in ITT analysis; natural history data will aid statistical analysis to account for crossover effects.

Other Key Points:

• Share Buyback: The $400M authorization signals financial maturity and confidence in the stock's intrinsic value.
• Japan Market: Pricing concluded provides visibility for 2027 launch; addressing GMO status complexity for the DEB community.
• Pipeline Diversification: Progress in rare dermatology (Gorlin, Haley-Haley), ophthalmology, respiratory (CF), and oncology demonstrates a multi-disease strategy.
• Operational Efficiency: G&A expenses decreased $3.8M YoY due to insurance proceeds reimbursing legal costs and reduced legal/marketing spend, offset by higher payroll.